Prognosis following acute myocardial infarction in patients with ECG evidence of left ventricular hypertrophy prior to infarction

Yotsukura, Masayuki; Suzuki, Jun; Yamaguchi, Takako; Sasaki, Kenji; Koide, Yasushi; Mizuno, Haruyoshi; Yoshino, Hideaki; Ishikawa, Kinya

doi:10.1016/s0022-0736(98)90039-5

Cited by 15 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Framingham Heart Study demonstrated an increased relative risk of developing cardiovascular disease for each 50 g/m 2 increment in LVMI (LVM index; RR 1.49 compared with 1.57, males compared with females) [37]. Furthermore, LVH predicts prognosis in high-risk patient groups, such as those with coronary heart disease [38], HF [39], diabetes [40], renal failure [41], hypertension [42], obesity and previous MI [43]. Pharmacological regression of LVH is associated with a reduction in cardiovascular risk [44].…”

Section: Structural Features Of Diabetic Cardiomyopathy and Their Funmentioning

confidence: 99%

Diabetic cardiomyopathy

et al. 2009

View full text Add to dashboard Cite

Diabetic cardiomyopathy is a distinct primary disease process, independent of coronary artery disease, which leads to heart failure in diabetic patients. Epidemiological and clinical trial data have confirmed the greater incidence and prevalence of heart failure in diabetes. Novel echocardiographic and MR (magnetic resonance) techniques have enabled a more accurate means of phenotyping diabetic cardiomyopathy. Experimental models of diabetes have provided a range of novel molecular targets for this condition, but none have been substantiated in humans. Similarly, although ultrastructural pathology of the microvessels and cardiomyocytes is well described in animal models, studies in humans are small and limited to light microscopy. With regard to treatment, recent data with thiazoledinediones has generated much controversy in terms of the cardiac safety of both these and other drugs currently in use and under development. Clinical trials are urgently required to establish the efficacy of currently available agents for heart failure, as well as novel therapies in patients specifically with diabetic cardiomyopathy.

show abstract

Section: Structural Features Of Diabetic Cardiomyopathy and Their Funmentioning

confidence: 99%

Diabetic cardiomyopathy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…5,6 Patients who present LVH are at considerable risk of developing CHD, congestive heart failure, stroke or sudden death. [5][6][7][8][9][10] In clinical practice, echocardiography is the best method for assessing of LVH. 11 In primary health care, however, echocardiography is too expensive and out of reach regarding human resources for rou-tine daily clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of left ventricular hypertrophy in Finnish primary health care hypertensive patients

et al. 2001

View full text Add to dashboard Cite

Background:Hypertensive patients who present left ventricular hypertrophy (LVH) are at considerable risk of developing cardiovascular complications. Echocardiography, being the best method for assessing of LVH, is too expensive for routine daily practice particularly in primary health care. Therefore, electrocardiogram (ECG) still remains the most feasible method to assess LVH in these settings. Objectives: The aim of this study was to determine the prevalence of ECG-LVH in Finnish hypertensive primary health care patients and evaluate the quality of their blood pressure control. Methods: A total of 255 general practitioners in 26 primary health care centres identified all of their hypertensive patients visiting during a 1-week period. A health examination was carried out on these patients by health

show abstract

“…The 12.5% prevalence of LV WM abnormalities in LIFE echo substudy patients is nearly 3 times higher than the 4.3% reported in hypertensive adults in the Cardiovascular Health Study. 5 One potential explanation is the selection of subjects with ECG LV hypertrophy for LIFE, in view of the known association of higher LV mass with CHD, 28,29 myocardial infarction, 18,30 and larger myocardial infarction size. 31,32 In fact, patients with segmental or global WM abnormalities had greater LV mass, as indicated by both ECG and echocardiographic methods, than those without systolic dysfunction.…”

Section: Discussionmentioning

confidence: 99%

Echocardiographic Wall Motion Abnormalities in Hypertensive Patients With Electrocardiographic Left Ventricular Hypertrophy

et al. 2003

View full text Add to dashboard Cite

Abstract-There is limited information on correlates of left ventricular wall motion (WM) abnormalities in ambulatory patients with hypertension and ECG left ventricular hypertrophy by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria. Therefore, we assessed the prevalence and the correlates of echocardiographic global and segmental left ventricular WM abnormalities in 942 hypertensive patients with hypertrophy enrolled in the Losartan Intervention For End-point reduction in hypertension (LIFE) echo substudy. Patients were separated into groups of those with normal WM or those with segmental or global WM abnormalities. Segmental and global WM abnormalities were mostly of mild degree and were detected in 7% and 6% of the study sample. Compared with subjects with normal motion, those with WM abnormalities were mostly men and had higher prevalences of self-reported coronary heart disease, ECG signs of myocardial infarction, ST-strain pattern, and higher Cornell voltage-duration product, echo-left ventricular mass, and albuminuria, but lower total and high-density lipoprotein cholesterol. Blood pressure was similar among groups. No significant differences were found between patients with global or segmental WM abnormalities.Only half of patients with WM abnormalities had a history or ECG signs of coronary heart disease. Independent correlates of WM abnormalities were higher albuminuria and Cornell voltage-duration product, male gender, and echo-left ventricular hypertrophy, but lower cholesterol. In a subanalysis restricted to patients with WM abnormalities, those with evident cardiovascular disease had a higher prevalence of ST-strain pattern than those with subclinical WM abnormalities, but other clinical, ECG, or echocardiographic parameters were indistinguishable between the 2 groups. Thus, in hypertensives with ECG left ventricular hypertrophy, WM abnormalities, mostly of mild degree, occurred in one eighth of the patients and were associated with male gender, left ventricular hypertrophy, and albuminuria. No significant differences were found between patients with global or segmental wall motion abnormalities. Key Words: hypertension, arterial Ⅲ echocardiography Ⅲ hypertrophy Ⅲ ventricular function, left Ⅲ coronary heart disease Ⅲ risk factors C oronary heart disease (CHD) is the leading cause of morbidity and mortality in hypertension. 1 Myocardial infarction or severe ischemia are the most common causes of left ventricular (LV) wall motion (WM) abnormalities, 2 which may reduce LV pump function. 3,4 However, information on the prevalence and correlates of WM abnormalities in ambulatory high-risk hypertensive patients is limited. 5 Hypertension is a major determinant of LV hypertrophy 1 and is associated with increased prevalence of LV systolic dysfunction. 6 However, global LV ejection fraction (EF), a measure of LV chamber function highly useful as an indicator of LV systolic dysfunction, can be normal despite segmental WM abnormalities, especially when EF is estimated from linear echocar...

show abstract

Prognosis following acute myocardial infarction in patients with ECG evidence of left ventricular hypertrophy prior to infarction

Cited by 15 publications

References 22 publications

Diabetic cardiomyopathy

Diabetic cardiomyopathy

Prevalence of left ventricular hypertrophy in Finnish primary health care hypertensive patients

Echocardiographic Wall Motion Abnormalities in Hypertensive Patients With Electrocardiographic Left Ventricular Hypertrophy

Contact Info

Product

Resources

About